We had the great pleasure of meeting with Andrew Blumenfeld (Director, Headache, The Neurology Center of Southern California, Carlsbad, CA, USA) to discuss the combination use of onabotulinumtoxinA and CGRP mAbs in the treatment of chronic migraine.
The abstract ‘Combination use of onabotulinumtoxinA and CGRP mAbs in the treatment of chronic migraine’ was presented at the American Headache Society (AHS) Virtual Annual Scientific Meeting 2021, 3-6 June 2021.
Questions:
- What is the rationale for the combination use of onabotulinumtoxinA and CGRP mAbs in the treatment of chronic migraine? (0:17)
- Could you tell us a little about the aims, method and findings of the longitudinal chart review you conducted? (1:56)
- What did we learn in terms of safety and tolerability? (9:18)
Disclosures: Andrew Blumenfeld is on the advisory board for Allergan, Abbvie, Aeon, Alder, Amgen, Axsome, Biohaven, Impel, Lundbeck, Lilly, Novartis, Revance, Teva, Theranica, and Zosano Pharma; a speaker for Allergan, Abbvie, Amgen, Biohaven, Lundbeck, Lilly, and Teva; a consultant for Allergan, Abbvie, Alder, Amgen, Biohaven, Lilly, Lundbeck, Novartis, Teva, and Theranica; receives grant support from Allergan and Amgen; and is a contributing author for Allergan, Abbvie, Amgen, Novartis, Teva, Lilly, and Biohaven.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of AHS Virtual Annual Scientific Meeting 2021
